Medincel

Medincell is a French commercial-stage biopharmaceutical company focused on long-acting injectable therapies enabled by its proprietary BEPO drug-delivery platform. The company develops and licenses formulations that can sustain release of established medicines for weeks to months, with the goal of improving adherence, access, and treatment outcomes. Its first commercial product is UZEDY, a long-acting subcutaneous risperidone for schizophrenia, commercialized by Teva. Medincell also has a partnered olanzapine long-acting injectable program that has reached NDA stage in the United States, plus earlier programs in pain management, contraception, and malaria prevention. The company primarily operates a partnering and licensing model with large pharmaceutical companies, global health organizations, and specialty developers.